Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tipranavir disodium
Drug ID BADD_D02227
Description Tipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets the HIV protease. Tipranavir and ritonavir are coadministered to treat HIV.
Indications and Usage For combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.
Marketing Status approved; investigational
ATC Code J05AE09
DrugBank ID DB00932
KEGG ID D03843
MeSH ID C107201
PubChem ID 163296
TTD Drug ID D0EV6T
NDC Product Code 0597-0003; 11014-0046; 12714-901
UNII 9BAN2XG1ZW
Synonyms tipranavir | tipranavir, (R-(R*,R*))-isomer | 3'-((1R)-1-((6R)-5,6-dihydro-4-hydroxy-2-oxo-6-phenethyl-6-propyl-2h-pyran-3-yl)propyl)-5-(trifluoromethyl)-2-pyridinesulfonanilide | Aptivus | tipranavir, (S-(R*,R*))-isomer | tipranavir, (S-(R*,S*))-isomer | tipranavir glucuronide | (2R)-3,6-Dihydro-6-oxo-2-(2-phenylethyl)-2-propyl-5-((1R)-1-(3-(((5-(trifluoromethyl)-2-pyridinyl)sulfonyl)amino)phenyl)propyl)-2H-pyran-4-yl beta-D-glucopyranosiduronic acid | tipranavir, (R-(R*,S*))-isomer | tipranavir C-14 | C14-tipranavir | 14C-tipranavir | tipranavir disodium | PNU-140690E | tipranavir sodium | PNU 140690 | PNU-140690
Chemical Information
Molecular Formula C31H31F3N2Na2O5S
CAS Registry Number 191150-83-1
SMILES CCCC1(CC(=C(C(=O)O1)C(CC)C2=CC(=CC=C2)[N-]S(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)[O-])CC C4=CC=CC=C4.[Na+].[Na+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Insomnia19.02.01.002; 17.15.03.002--
Insulin resistance05.06.02.003; 14.06.02.003--Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Lipase increased13.05.01.003--
Lipoatrophy23.07.01.001; 14.08.04.006--
Liver disorder09.01.08.001--Not Available
Liver function test abnormal13.03.04.030--Not Available
Lymphoma16.20.01.001; 01.12.01.001--Not Available
Malaise08.01.01.003--
Muscle haemorrhage12.01.07.016; 24.07.01.037; 15.05.03.017--Not Available
Muscle spasms15.05.03.004--
Myalgia15.05.02.001--
Myositis15.05.01.001--
Nausea07.01.07.001--
Neoplasm16.16.02.001--Not Available
Nervous system disorder17.02.10.001--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Neutropenia01.02.03.004--Not Available
Non-Hodgkin's lymphoma16.35.01.001; 01.17.01.001--Not Available
Oesophageal candidiasis11.03.03.008; 07.19.06.001--Not Available
Opportunistic infection11.01.08.007--Not Available
Pain08.01.08.004--
Pancreatitis07.18.01.001--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pneumonia streptococcal22.07.06.006; 11.02.06.005--Not Available
Pregnancy18.08.02.004--Not Available
Progressive multifocal leukoencephalopathy11.05.05.001; 17.16.02.002--Not Available
Prurigo23.03.04.017--Not Available
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages